Close Menu

NEW YORK – Quest Diagnostic said on Monday that it expects Q2 2020 revenues to be approximately $1.83 billion, down roughly 6 percent year-over-year but above the consensus Wall Street estimate of $1.5 billion

The company said that the better-than-expected revenues reflected a "stronger than forecasted recovery in base testing volumes… as well as growing demand for COVID-19 testing services."

Total test volume for the quarter is expected to be down by roughly 18 percent year-over-year, with test volume excluding SARS-CoV-2 testing down around 34 percent versus Q2 2019.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Sponsored by

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.